Home Cart Sign in  
Chemical Structure| 67915-31-5 Chemical Structure| 67915-31-5

Structure of Terconazole
CAS No.: 67915-31-5

Chemical Structure| 67915-31-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Terconazole is used to treat vaginal yeast infection, working by disrupting the biosynthesis of fats in a yeast cell.

Synonyms: R42470; NSC 331942; Gyno-Terazol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Terconazole

CAS No. :67915-31-5
Formula : C26H31Cl2N5O3
M.W : 532.46
SMILES Code : CC(N1CCN(C2=CC=C(OC[C@@H]3O[C@](C4=CC=C(Cl)C=C4Cl)(CN5N=CN=C5)OC3)C=C2)CC1)C
Synonyms :
R42470; NSC 331942; Gyno-Terazol
MDL No. :MFCD05662369

Safety of Terconazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335-H413
Precautionary Statements:P261-P273-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00503542 Vaginitis Early Phase 1 Completed - United States, New York ... More >> Family Health Center Bronx, New York, United States, 10458 Less <<
NCT01813162 HIV Prevention Phase 1 Completed - United States, California ... More >> Dept of OBGYN and Reproductive Sciences, UCSF San Francisco, California, United States United States, New York Bronx-Lebanon Hospital Center Bronx, New York, United States Less <<
NCT02308007 Vaginal Infection Phase 3 Completed - -
NCT01867164 Vaginitis Inf... More >>ectious Vaginosis Less << Phase 3 Completed - Mexico ... More >> DF, Mexico Mexico D.F., Mexico Less <<
NCT02308033 Vaginal Infection Phase 3 Completed - -
NCT02308046 Vaginal Infection Phase 3 Completed - -
NCT03473418 Vaginal Candidiasis Phase 3 Not yet recruiting April 1, 2019 -
NCT00803738 Vulvovaginal Candidiasis Not Applicable Completed - -
NCT02180100 Vulvovaginal Candidiasis Phase 4 Completed - China, Guangdong ... More >> Peking University Shenzhen Hosptal Shenzhen, Guangdong, China, 518036 Less <<
NCT01867164 - Completed - -
NCT00803738 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.39mL

1.88mL

0.94mL

18.78mL

3.76mL

1.88mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories